Stephen Benoit, President & CEO

(Assistant CEO)

<strong>Stephen Benoit<br>President & CEO</strong><br><font align=”justify”>Stephen Benoit brings to <i>MDI Therapeutics</i> broad experience in VC-backed start-ups and small and large-cap public companies in the pharmaceuticals, food & agriculture biotechnology, food safety training and education, consumer packaged foods, and specialty ingredients industries. Prior to joining <i>MDI Therapeutics</i>, Mr. Benoit was CEO of <a href=”http://www.msdrx.com”>Metabolic Solutions Development Company</a> (MSDC), a clinical-stage developer of small molecule therapeutics to treat diseases associated with metabolic dysfunction. During Mr. Benoit’s tenure, MSDC raised more than $70 million from top-tier and regional VC’s, family offices, angels, and high net worth individuals, including a recent $40 million financing for a new spinout company (<a href=”http://www.ciriustx.com”>Cirius Therapeutics</a>) developing MSDC’s Phase 2b program for the treatment of NASH, which was led by <a href=”http://www.frazierhealthcare.com/”>Frazier Healthcare Partners</a>, <a href=”http://www.novoholdings.dk/ventures/about”>Novo Ventures</a>. In addition, the company successfully completed three Phase 2 clinical trials (diabetes, Alzheimer’s) and several collaborations with academic researchers (NASH, PKD, Parkinson’s), and made significant advances in a small molecule drug discovery program (metabolic diseases). Mr. Benoit continues to serve on the MSDC Board of Managers, and is a consultant to Cirius Therapeutics.

Prior to MSDC, Mr. Benoit was the Founding President & COO of the <a href=”http://www.iftpi.com”>International Food Protection Training Institute</a>, and a co-founder, President & CEO of NanoMed Pharmaceuticals, a developer of nanoparticle-formulated therapeutic agents to treat cancer. Previously, he held senior management positions with a developer of direct-to-consumer personal genetic assessments, a Fortune 250 global food manufacturing company, a small-cap public company that developed and manufactured antimicrobial peptides for food and animal health products, and a small-cap public company that pioneered food & agricultural biotechnology. He began his career at Bank of America.

Mr. Benoit earned a Masters of Business Administration, Finance and a Bachelor of Business Administration, Finance from Loyola Marymount University (Los Angeles). He has been a Visiting Executive Lecturer at the University of Virginia, Darden School of Business, (Post-Merger Integrations) and Western Michigan University (Functional Foods).</font>